Want to see HK:2591 full AI Analyst Report?
Top Page
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
(2591)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$6.50
▼(-78.63% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by weak financial quality (large ongoing losses and negative free cash flow despite a 2025 revenue ramp) and bearish technicals (price far below key moving averages with negative MACD). Valuation does not offset these risks because the company is still loss-making (negative P/E) and no dividend support is indicated.
Positive Factors
Revenue ramp & high gross margin
The sharp 2025 revenue inflection alongside an ~81.5% gross margin signals early commercialization with attractive unit economics. Durable high gross margins can scale to absorb fixed R&D and SG&A costs, enabling structural margin improvement as revenues grow over the next several quarters.
Negative Factors
Large ongoing cash losses
Persistent negative operating and free cash flow at scale demonstrates the business still consumes material liquidity. Continued large cash deficits require ongoing balance-sheet support and elevate the probability of dilution, covenant strain or program cuts if revenue growth or margin gains underperform expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue ramp & high gross margin
The sharp 2025 revenue inflection alongside an ~81.5% gross margin signals early commercialization with attractive unit economics. Durable high gross margins can scale to absorb fixed R&D and SG&A costs, enabling structural margin improvement as revenues grow over the next several quarters.
Read all positive factors
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.24B
Dividend YieldN/A
Average Volume (3M)470.32K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS Growth-102.03%
CountryHK
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume352,882
30 Day Avg. Volume470,322
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.10Price Target Upside-7.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Business Overview & Revenue Model
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, an...
How the Company Makes Money
null...
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 128.11M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 104.43M | -17.28M | -19.65M | -19.08M |
| EBITDA | -324.30M | -156.89M | -711.42M | -308.37M |
| Net Income | -332.53M | -174.69M | -733.38M | -306.99M |
Balance Sheet | ||||
| Total Assets | 1.57B | 934.80M | 1.11B | 668.71M |
| Cash, Cash Equivalents and Short-Term Investments | 1.21B | 796.88M | 945.34M | 501.37M |
| Total Debt | 166.33M | 9.90M | 46.59M | 50.31M |
| Total Liabilities | 517.84M | 138.33M | 400.24M | 135.23M |
| Stockholders Equity | 1.05B | 796.47M | 705.13M | 533.48M |
Cash Flow | ||||
| Free Cash Flow | -317.57M | -166.95M | -176.79M | -226.17M |
| Operating Cash Flow | -295.54M | -162.62M | -164.60M | -197.33M |
| Investing Cash Flow | 22.63M | 275.95M | -157.21M | -77.24M |
| Financing Cash Flow | 722.37M | 254.84M | 351.71M | 9.95M |
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$68.70B | 57.13 | 42.27% | ― | 80.08% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$6.77B | -55.90 | -6.26% | ― | -11.65% | -169.40% | |
45 Neutral | HK$3.76B | -22.20 | -17.64% | ― | -65.87% | 6.71% | |
44 Neutral | HK$3.24B | -7.96 | -38.11% | ― | ― | -102.03% | |
44 Neutral | HK$8.59B | -68.31 | -11.21% | ― | 219.26% | 87.63% | |
44 Neutral | HK$12.30B | -8.30 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:2591
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
7.09
-45.51
-86.52%
HK:9966
Alphamab Oncology
6.95
0.85
13.93%
HK:9995
RemeGen Co. Ltd. Class H
74.30
19.85
36.46%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.78
0.20
4.37%
HK:2171
CARsgen Therapeutics Holdings Ltd.
14.26
-8.84
-38.27%
HK:6855
Ascentage Pharma Group International
33.20
-44.90
-57.49%
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Corporate Events
Guangzhou Innogen Wins Strong Shareholder Backing at 2026 AGM
Jun 29, 2026
Guangzhou Innogen Pharmaceutical Group Co., Ltd. reported that shareholders overwhelmingly approved all ordinary resolutions at its annual general meeting held in Shanghai on June 29, 2026, including the 2025 board and supervisory reports, audited...
Guangzhou Innogen Sets Formal Audit Committee Mandate to Strengthen Governance
Jun 29, 2026
Guangzhou Innogen Pharmaceutical Group has established an Audit Committee under its board to strengthen decision-making, enhance internal controls and improve corporate governance in line with PRC company law and Hong Kong Listing Rules. The commi...
Guangzhou Innogen Wins NMPA Nod for Adolescent Obesity Trial
Jun 22, 2026
Guangzhou Innogen Pharmaceutical Group has received regulatory clearance from China’s National Medical Products Administration to begin a Phase Ib clinical trial of Efsubaglutide Alfa for treating obesity in adolescents. The company plans to...
Guangzhou Innogen Sets 2026 AGM to Approve 2025 Results and Board Re-elections
Jun 5, 2026
Guangzhou Innogen Pharmaceutical Group Co., Ltd. has convened its annual general meeting for 29 June 2026 in Shanghai, where shareholders will review the 2025 board and supervisory committee reports, audited consolidated financial statements and t...
Guangzhou Innogen Proposes New Share Award Scheme to Strengthen Incentives
Jun 1, 2026
Guangzhou Innogen Pharmaceutical Group plans to adopt a new share award scheme, subject to shareholder approval and Stock Exchange listing consent, to grant share-based incentives to employees, related entity staff and service providers. The initi...
Guangzhou Innogen Seeks Board Re-Election and Governance Updates
Jun 1, 2026
Guangzhou Innogen Pharmaceutical Group has proposed the re-election of all existing board members for a new three-year term, subject to shareholder approval at the upcoming annual general meeting. The slate includes four executive, two non-executi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.